排序方式:
日期(降序)
日期(升序)
標題(降序)
標題(升序)
WOS引用數(降序)
WOS引用數(升序)
2.Identification of an IKK beta inhibitor for inhibition of inflammation in vivo and in vitro
Chen, Q, Liu, J, Zhu
More...
Chen, Q, Liu, J, Zhuang, YX, Bai, LP, Yuan, Q, Zheng, SL, Liao, KS, Khan, MA, Wu, QB, Luo, C, Liu, L, Wang, H, Li, T
Less
PHARMACOLOGICAL RESEARCH[1043-6618],
Published 2019,
Volume 149,
收錄情况:
WOS
SCOPUS
WOS核心合集引用: 14
2023影響因子:
9.1
发表年影響因子:
5.893
3.Artificial intelligence-based collaborative filtering method with ensemble learning for personalized lung cancer medicine without genetic sequencing
Luo, Shengda, Liu, L
More...
Luo, Shengda, Liu, Lei, Leung, Alex Po, Xu, Jiahui, Jiang, Zebo, Wu, Qibiao, Leung, Elaine LaiHan
Less
Pharmacological Research[1043-6618],
Published 2020,
Volume 160,
收錄情况:
WOS
SCOPUS
WOS核心合集引用: 11
2023影響因子:
9.1
发表年影響因子:
7.658
4.Chelidonine selectively inhibits the growth of gefitinib-resistant non-small cell lung cancer cells through the EGFR-AMPK pathway
Xie, YaJia, Gao, Wei
More...
Xie, YaJia, Gao, WeiNa, Wu, QiBiao, Yao, XiaoJun, Jiang, ZeBo, Wang, YuWei, Wang, WenJun, Hussain, Shahid, Liu, Liang, Leung, Elaine LaiHan, Fan, XingXing, Li, Wei
Less
Pharmacological Research[1043-6618],
Published 2020,
Volume 159,
收錄情况:
WOS
SCOPUS
WOS核心合集引用: 26
2023影響因子:
9.1
发表年影響因子:
7.658
5.Plumbagin suppresses non-small cell lung cancer progression through downregulating ARF1 and by elevating CD8+ T cells
Jiang, ZeBo, Xu, Con
More...
Jiang, ZeBo, Xu, Cong, Wang, Wenjun, Zhang, YiZhong, Huang, JuMin, Xie, YaJia, Wang, QianQian, Fan, XingXing, Yao, XiaoJun, Xie, Chun, Wang, XuanRun, Yan, PeiYu, Ma, YuPo, Wu, QiBiao, Leung, Elaine LaiHan
Less
Pharmacological Research[1043-6618],
Published 2021,
Volume 169,
收錄情况:
WOS
SCOPUS
WOS核心合集引用: 17
2023影響因子:
9.1
发表年影響因子:
10.334
6.Andrographolide suppresses non-small-cell lung cancer progression through induction of autophagy and antitumor immune response
Wang, Xuan-Run,Jiang
More...
Wang, Xuan-Run,Jiang, Ze-Bo,Xu, Cong,Meng, Wei-Yu,Liu, Pei,Zhang, Yi-Zhong,Xie, Chun,Xu, Jing-Yi,Xie, Ya-Jia,Liang, Tu-Liang,Yan, Hao-Xin,Fan, Xing-Xing,Yao, Xiao-Jun,Wu, Qi-Biao,Leung, Elaine Lai-Han
Less
Pharmacological Research[1043-6618],
Published 2022,
Volume 179,
收錄情况:
WOS
SCOPUS
WOS核心合集引用: 35
2023影響因子:
9.1
发表年影響因子:
9.3
7.β-Elemene enhances erlotinib sensitivity through induction of ferroptosis by upregulating lncRNA H19 in EGFR-mutant non-small cell lung cancer.
Xu, Cong, Jiang, Ze
More...
Xu, Cong, Jiang, Ze Bo, Shao, Le, Zhao, Zi Ming, Fan, Xing Xing, Sui, Xinbing, Yu, Li Li, Wang, Xuan Run, Zhang, Ruo Nan, Wang, Wen Jun, Xie, Ya Jia, Zhang, Yi Zhong, Nie, Xiao Wen, Xie, Chun, Huang, Ju Min, Wang, Jing, Wang, Jue, Leung, Elaine Lai Han, Wu, Qi Biao
Less
Pharmacological Research[1043-6618],
Published 2023,
Volume 191,
收錄情况:
WOS
SCOPUS
WOS核心合集引用: 29
2023影響因子:
9.1
发表年影響因子:
9.1
8.CERS4 predicts positive anti-PD-1 response and promotes immunomodulation through Rhob-mediated suppression of CD8+Tim3+ exhausted T cells in non-small cell lung cancer.
Wang, J, Li, RZ, Wan
More...
Wang, J, Li, RZ, Wang, WJ, Pan, HD, Xie, C, Yau, LF, Wang, XX, Long, WL, Chen, RH, Liang, TL, Ma, LR, Li, JX, Huang, JM, Wu, QB, Liu, L, He, JX, Leung, ELH
Less
PHARMACOLOGICAL RESEARCH[1043-6618],
Published 2023,
Volume 194,
收錄情况:
WOS
SCOPUS
WOS核心合集引用: 6
2023影響因子:
9.1
发表年影響因子:
9.1